(Reuters) -The U.S. Food and Drug Administration has approved Axsome Therapeutics’ migraine treatment, the company said on Thursday.
The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.
Symbravo is a combination of two compounds, meloxicam and rizatriptan, designed to provide rapid and sustained relief to acute migraine pain, Axsome said.
The company expects the drug to be commercially available in the U.S. in about four months.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Comments